Market by Product Type, Therapeutic Application, and End-user | Forecast 2023-2028
Triton Market Research’s report predicts that
the market for botulinum toxin type A in Taiwan is set to witness a CAGR of 11.30% over the forecasted phase 2023-2028. It is predicted to obtain
revenue worth $XX million by 2028.
The pure form of botulinum toxin, called miracle poison or botulinum
toxin type A, is derived from Clostridium botulinum bacteria. It paralyzes by
blocking acetylcholine release at neuromuscular junctions. Medically and
cosmetically, it’s used to treat crow’s feet, glabellar lines, forehead
wrinkles, conditions like abnormal muscle contractions, and autonomic disorders
such as sialorrhea, hyperhidrosis, and hypersalivation.
Recently, it has been used to treat myofascial
pain syndrome, tension headaches, and migraines. Botulinum toxin type A is used
off-label for several conditions, including neurogenic thoracic outlet
syndrome, myofascial pain, post-herpetic neuralgia, epicondylitis, post-stroke
pain, trigeminal neuralgia, diabetic neuropathy, neuropathic pain, spinal cord
injury, and bladder pain.
The most popular preparation, botulinum toxin
type A, is available in commercially viable versions in Taiwan: Botox®
(Allergan Pharmaceuticals), Xeomin® (Merz Pharmaceuticals), Meditoxin® (Medytox
Inc), and Dysport® (Ipsen Pharmaceuticals). The Taiwan Food and Drug
Administration also approved Daewoong Pharmaceutical’s Nabota, a type A
botulinum toxin used only to cure frown lines.
Many key players are conducting phase II and III
prospective, controlled, randomized, double-blinded studies to assess botulinum
toxin’s efficacy and molecular mechanism in reducing breast reduction
mammoplasty scar formation. Hence, it has found a major market segment for
therapeutic applications, thereby boosting the Taiwan botulinum toxin type A
market.
Triton Market Research’s report provides
in-depth insight into the Taiwan botulinum toxin type A market, along with
segmentation analysis. The detailed analysis of the market includes PEST
analysis, current market trends, regulatory framework, and insurance system &
reimbursements. The segmentation analysis
includes market by product type, therapeutic application, and end-user.
The
major players in the botulinum toxin type A market are AbbVie Inc, Merz Pharma,
Ipsen Pharma, and Hugel Inc.
Market By Type, Application, E ..
VIEW REPORT
Market By Device Type, Therape ..
VIEW REPORT
Market By Type, Application, T ..
VIEW REPORT
Market By Technology, Applicat ..
VIEW REPORT
Market By Application, Type, E ..
VIEW REPORT
Market by Therapeutics, Diagno ..
VIEW REPORT
Market by Type, Application, E ..
VIEW REPORT1. TAIWAN
BOTULINUM TOXIN TYPE A MARKET – SUMMARY
1.1. MARKET
SIZE & FORECAST
1.2. COUNTRY
ANALYSIS
1.3. MARKET
DRIVING ASPECTS
1.3.1. EXPANSION
OF BOTULINUM TOXIN INTO NON-DERMATOLOGICAL APPLICATIONS
1.3.2. GROWING
PREFERENCE FOR NON-INVASIVE TREATMENTS
1.4. MARKET
RESTRAINING ASPECT
1.4.1. SIDE
EFFECTS OF BOTULINUM TOXIN
2. TAIWAN
BOTULINUM TOXIN TYPE A MARKET OUTLOOK
2.1. PEST
ANALYSIS
2.2. CURRENT
MARKET TRENDS
2.3. KEY
MARKET STRATEGIES
2.3.1. COLLABORATIONS
2.3.2. PRODUCT
LAUNCHES AND DEVELOPMENTS
2.3.3. ACQUISITIONS
2.4. POTENTIAL
FOR NEW ENTRANTS IN TAIWAN BOTULINUM TYPE A MARKET
2.5. MARKET
ATTRACTIVENESS INDEX
2.6. REGULATORY
FRAMEWORK
2.7. INSURANCE
SYSTEM AND REIMBURSEMENTS
2.7.1. HEALTHCARE
& INSURANCE SYSTEM
2.7.2. REIMBURSEMENT
FOR THERAPEUTIC BOTOX TREATMENT
3. TAIWAN
BOTULINUM TOXIN TYPE A MARKET OUTLOOK - BY PRODUCT TYPE
3.1. ABOBOTULINUMTOXIN
TYPE A
3.2. INCOBOTULINUMTOXIN
TYPE A
3.3. ONABOTULINUMTOXIN
TYPE A
4. TAIWAN
BOTULINUM TOXIN TYPE A MARKET OUTLOOK - BY THERAPEUTIC APPLICATION
4.1. CHRONIC
MIGRAINE
4.2. SPASTIC
DISORDERS
4.3. CERVICAL
DYSTONIA
4.4. DETRUSOR
OVERACTIVITY
4.5. OTHER
THERAPEUTIC APPLICATIONS
5. TAIWAN
BOTULINUM TOXIN TYPE A MARKET OUTLOOK - BY END-USER
5.1. HOSPITALS
AND CLINICS
5.2. OTHER
END-USERS
6. COMPETITIVE
LANDSCAPE
6.1. ABBVIE
INC
6.2. HUGEL
INC
6.3. IPSEN
PHARMA
6.4. MERZ
PHARMA
6.5. MEDYTOX
INC
7. RESEARCH
METHODOLOGY & SCOPE
7.1. RESEARCH
SCOPE & DELIVERABLES
7.2. SOURCES
OF DATA
7.3. RESEARCH
METHODOLOGY
TABLE 1: REGULATORY FRAMEWORK
FOR TAIWAN BOTULINUM TOXIN TYPE A MARKET
TABLE 2: NUMBER OF MEDICAL
INSTITUTIONS IN TAIWAN 2020-2021
TABLE 3: TAIWAN BOTULINUM
TOXIN TYPE A MARKET, BY PRODUCT TYPE, 2023-2028 (IN $ MILLION)
TABLE 4: TAIWAN BOTULINUM
TOXIN TYPE A MARKET, BY THERAPEUTIC APPLICATION, 2023-2028 (IN $ MILLION)
TABLE 5: TAIWAN BOTULINUM
TOXIN TYPE A MARKET, BY END-USER, 2023-2028 (IN $ MILLION)
TABLE 6: LIST OF BOTULINUM
TOXIN TYPE A MARKET COLLABORATIONS
TABLE 7: LIST OF BOTULINUM
TOXIN TYPE A MARKET PRODUCT LAUNCHES & DEVELOPMENTS
TABLE 8: LIST OF BOTULINUM
TOXIN TYPE A MARKET ACQUISITIONS
FIGURE 1: NON-DERMATOLOGICAL
APPLICATIONS OF BOTULINUM TOXIN
FIGURE 2: MARKET
ATTRACTIVENESS INDEX
FIGURE 3: TAIWAN BOTULINUM
TOXIN TYPE A MARKET, BY PRODUCT TYPE, 2022 & 2028 (IN %)
FIGURE 4: TAIWAN BOTULINUM
TOXIN TYPE A MARKET, BY ABOBOTULINUMTOXIN TYPE A, 2023-2028 (IN $ MILLION)
FIGURE 5: TAIWAN BOTULINUM
TOXIN TYPE A MARKET, BY INCOBOTULINUMTOXIN TYPE A, 2023-2028 (IN $ MILLION)
FIGURE 6: TAIWAN BOTULINUM
TOXIN TYPE A MARKET, BY ONABOTULINUMTOXIN TYPE A, 2023-2028 (IN $ MILLION)
FIGURE 7: TAIWAN BOTULINUM
TOXIN TYPE A MARKET, BY THERAPEUTIC APPLICATION, 2022 & 2030 (IN %)
FIGURE 8: TAIWAN BOTULINUM
TOXIN TYPE A MARKET, BY CHRONIC MIGRAINE, 2023-2028 (IN $ MILLION)
FIGURE 9: TAIWAN BOTULINUM
TOXIN TYPE A MARKET, BY SPASTIC DISORDERS, 2023-2028 (IN $ MILLION)
FIGURE 10: TAIWAN BOTULINUM
TOXIN TYPE A MARKET, BY CERVICAL DYSTONIA, 2023-2028 (IN $ MILLION)
FIGURE 11: TAIWAN BOTULINUM
TOXIN TYPE A MARKET, BY DETRUSOR OVERACTIVITY, 2023-2028 (IN $ MILLION)
FIGURE 12: TAIWAN BOTULINUM
TOXIN TYPE A MARKET, BY OTHER THERAPEUTIC APPLICATIONS, 2023-2028 (IN $
MILLION)
FIGURE 13: TAIWAN BOTULINUM
TOXIN TYPE A MARKET, BY END-USER, 2022 & 2030 (IN %)
FIGURE 14: TAIWAN BOTULINUM
TOXIN TYPE A MARKET, BY HOSPITALS AND CLINICS, 2023-2028 (IN $ MILLION)
FIGURE 15: TAIWAN BOTULINUM
TOXIN TYPE A MARKET, BY OTHER END-USERS, 2023-2028 (IN $ MILLION)